arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Humacyte, Inc.

HUMA

$0.72 ▲ +0.02 (+2.36%) at close

7 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Humacyte, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $113.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -280.5% ↘

FCF / Share $-0.67 ↗

Trailing P/E —

Price / Book 44.7x

FCF Yield —

Debt / Equity 11.40

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.04M

— —

Net Income Profit after all expenses

$-40.83M

↑ +72.5% —

FCF / Share Free cash flow per share

$-0.67

↑ +20.4% —

Long-Term Debt Long-term obligations

$35.44M

— —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	79.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-17.8% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-791.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	81.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	94.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	72.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-34.2% Weak ↑ Weak Improving Year-over-year change in net income	-825.8% Weak ↓ Weak Declining Year-over-year change in net income	54.8% Excellent Excellent Year-over-year change in net income	60.2% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	20.4% Good ↑ Good Improving Year-over-year change in free cash flow	-15.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	-4.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	65.6% Excellent Excellent Year-over-year change in free cash flow	79.0% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—
FCF / Net Income (x)	2.59x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	6.03x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	3.07x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-280.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	171.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-583.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-57.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	14.6% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-92.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-83.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-78.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-28.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-60.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	282.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1782%)	—	-10.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-168%)	-21.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	19.0% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+27%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	11.40x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+1800%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	0.25x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-59%)	—	—
Interest Coverage (x)	—	—	-15.16x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-13.64x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-18.68x Weak Weak Operating income divided by interest expense Optimal: > 5x	-29.34x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-15.05M	$-44.94M	$-80.45M	$-149.77M	$-187.50M	$-39.93M	—
Debt / EBITDA (x)	-0.34x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	-0.40x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.01	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.26	$-1.26	$-1.07	$-0.12	$-0.66	$-11.54	—
Free Cash Flow per Share (USD)	$-0.67	$-0.84	$-0.73	$-0.70	$-2.04	$-9.69	—
Book Value per Share (USD)	$0.02	$-0.41	$0.13	$1.13	$1.19	$-60.17	—
Tangible Book Value per Share (USD)	$0.02	$-0.41	$0.13	$1.13	$1.19	$-60.17	—
Basic Weighted Avg Shares (shares)	158.16M	118.48M	103.42M	103.05M	39.97M	5.77M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$49.42M	$27.91M	$64.83M	$134.63M	$218.29M	$30.22M	—
LT Debt (USD)	$35.44M	$0.00	—	—	$30.00M	—	—
Total Equity (USD)	$3.11M	$-52.67M	$13.55M	$116.93M	$122.17M	$-350.32M	$-288.79M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$2.04M	$0.00	—	—	—	—	—
Depreciation Expense (USD)	$5.33M	$5.10M	$5.66M	$6.15M	$6.18M	$6.29M	—
Net Income, GAAP (USD)	$-40.83M	$-148.70M	$-110.78M	$-11.96M	$-26.48M	$-66.52M	—
Operating Cash Flow (USD)	$-105.04M	$-98.12M	$-73.31M	$-71.13M	$-81.19M	$-55.57M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Humacyte, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare HUMA with peers